Loretta Jacques

2.9k total citations · 2 hit papers
69 papers, 2.0k citations indexed

About

Loretta Jacques is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Animal Science and Zoology. According to data from OpenAlex, Loretta Jacques has authored 69 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Physiology, 51 papers in Pulmonary and Respiratory Medicine and 8 papers in Animal Science and Zoology. Recurrent topics in Loretta Jacques's work include Asthma and respiratory diseases (61 papers), Respiratory and Cough-Related Research (42 papers) and Inhalation and Respiratory Drug Delivery (32 papers). Loretta Jacques is often cited by papers focused on Asthma and respiratory diseases (61 papers), Respiratory and Cough-Related Research (42 papers) and Inhalation and Respiratory Drug Delivery (32 papers). Loretta Jacques collaborates with scholars based in United Kingdom, United States and South Africa. Loretta Jacques's co-authors include N Ringdal, Ann J. Woolcock, Bo Lundbäck, Eric D. Bateman, Ashley Woodcock, Jan Lötvall, Eugene R. Bleecker, Paul M. O’Byrne, Richard Forth and Brett Haumann and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Gastroenterology.

In The Last Decade

Loretta Jacques

68 papers receiving 1.9k citations

Hit Papers

Comparison of Addition of Salmeterol to Inhaled Steroids ... 1996 2026 2006 2016 1996 2024 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Comparison of Addition of Salmeterol to Inhaled Steroids With Doubling of the Dose of Inhaled Steroids
    1996 569 citations Ann J. Woolcock, Bo Lundbäck et al. American Journal of Respiratory and Critical Care Medicine profile →
  2. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype
    2024 47 citations David J. Jackson, Michael E. Wechsler et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Loretta Jacques United Kingdom 21 1.7k 1.6k 208 196 144 69 2.0k
P.W. Ind United Kingdom 16 1.3k 0.8× 1.1k 0.7× 337 1.6× 177 0.9× 98 0.7× 33 1.8k
Petra Moroni-Zentgraf Germany 20 1.8k 1.0× 1.7k 1.1× 156 0.8× 135 0.7× 28 0.2× 78 1.9k
V SWYSTUN Canada 8 993 0.6× 729 0.5× 304 1.5× 97 0.5× 37 0.3× 10 1.1k
M J Cushley United Kingdom 14 636 0.4× 504 0.3× 53 0.3× 107 0.5× 58 0.4× 20 984
M. Van Der Straeten Belgium 14 461 0.3× 352 0.2× 109 0.5× 104 0.5× 136 0.9× 39 766
Unnur Steina Björnsdóttir Iceland 15 461 0.3× 289 0.2× 90 0.4× 161 0.8× 19 0.1× 23 808
Nicki M. Nair United States 8 640 0.4× 474 0.3× 192 0.9× 52 0.3× 20 0.1× 12 825
L. C. Laursen Denmark 14 238 0.1× 272 0.2× 145 0.7× 31 0.2× 15 0.1× 30 556
Chiharu Okada Japan 15 294 0.2× 333 0.2× 96 0.5× 105 0.5× 43 0.3× 48 694
Ronald J. Dandurand Canada 18 387 0.2× 465 0.3× 27 0.1× 171 0.9× 28 0.2× 37 756

Countries citing papers authored by Loretta Jacques

Since Specialization
Citations

This map shows the geographic impact of Loretta Jacques's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Loretta Jacques with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Loretta Jacques more than expected).

Fields of papers citing papers by Loretta Jacques

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Loretta Jacques. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Loretta Jacques. The network helps show where Loretta Jacques may publish in the future.

Co-authorship network of co-authors of Loretta Jacques

This figure shows the co-authorship network connecting the top 25 collaborators of Loretta Jacques. A scholar is included among the top collaborators of Loretta Jacques based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Loretta Jacques. Loretta Jacques is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jackson, David J., Michael E. Wechsler, Daniel J. Jackson, et al.. (2024). Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. New England Journal of Medicine. 391(24). 2337–2349. 47 indexed citations breakdown →
2.
Harvey, Catherine, Ashley Woodcock, Jørgen Vestbo, et al.. (2021). Safety data in randomised real-world evidence studies: Salford Lung Study learnings. ERJ Open Research. 7(2). 966–2020. 1 indexed citations
3.
Leather, David, Rupert Jones, Ashley Woodcock, et al.. (2020). Real-World Data and Randomised Controlled Trials: The Salford Lung Study. Advances in Therapy. 37(3). 977–997. 9 indexed citations
4.
5.
Svedsäter, Henrik, Rupert Jones, Nick Bosanquet, et al.. (2018). Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study. Respiratory Medicine. 141. 198–206. 14 indexed citations
6.
7.
Clark, Marci, Susan Martin, Henrik Svedsäter, Peter Dale, & Loretta Jacques. (2014). Measurement properties of an asthma symptom and rescue medication use diary. Journal of Asthma. 52(1). 88–97. 8 indexed citations
8.
Lin, Jiangtao, Jian Kang, Sang Haak Lee, et al.. (2014). Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: A randomized trial. Respiratory Medicine. 109(1). 44–53. 18 indexed citations
9.
Bleecker, Eugene R., Jan Lötvall, Paul M. O’Byrne, et al.. (2014). Fluticasone Furoate–Vilanterol 100-25 mcg Compared with Fluticasone Furoate 100 mcg in Asthma: A Randomized Trial. The Journal of Allergy and Clinical Immunology In Practice. 2(5). 553–561. 39 indexed citations
10.
11.
Lötvall, Jan, Eugene R. Bleecker, Paul M. O’Byrne, et al.. (2013). Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: A 24-week placebo and active-controlled randomised trial. Respiratory Medicine. 108(1). 41–49. 31 indexed citations
12.
Bateman, Eric D., Paul M. O’Byrne, Jan Lötvall, et al.. (2013). Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax. 69(4). 312–319. 61 indexed citations
13.
Woodcock, Ashley, Eugene R. Bleecker, Jan Lötvall, et al.. (2013). Efficacy and Safety of Fluticasone Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma. CHEST Journal. 144(4). 1222–1229. 73 indexed citations
14.
Bateman, Eric D., Eugene R. Bleecker, Jan Lötvall, et al.. (2012). Dose effect of once-daily fluticasone furoate in persistent asthma: A randomized trial. Respiratory Medicine. 106(5). 642–650. 57 indexed citations
15.
Bleecker, Eugene R., Eric D. Bateman, Ashley Woodcock, et al.. (2012). Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Annals of Allergy Asthma & Immunology. 109(5). 353–358.e4. 45 indexed citations
16.
Lötvall, Jan, Eric D. Bateman, Eugene R. Bleecker, et al.. (2012). 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. European Respiratory Journal. 40(3). 570–579. 61 indexed citations
17.
Woodcock, Ashley, Eugene R. Bleecker, Jan Lötvall, et al.. (2011). Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respiratory Research. 12(1). 160–160. 38 indexed citations
18.
Bateman, Eric D., et al.. (2006). Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. Journal of Allergy and Clinical Immunology. 117(3). 563–570. 75 indexed citations
19.
Woolcock, Ann J., Bo Lundbäck, N Ringdal, & Loretta Jacques. (1996). Comparison of Addition of Salmeterol to Inhaled Steroids With Doubling of the Dose of Inhaled Steroids. American Journal of Respiratory and Critical Care Medicine. 153(5). 1481–1488. 569 indexed citations breakdown →
20.
Pedersen, B., et al.. (1995). Once daily fluticasone propionate aqueous nasal spray controls symptoms of most patients with seasonal allergic rhinitis. Allergy. 50(10). 794–799. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P.W. Ind Breakdown of academic impact, for papers by Petra Moroni-Zentgraf Breakdown of academic impact, for papers by V SWYSTUN Breakdown of academic impact, for papers by M J Cushley Breakdown of academic impact, for papers by M. Van Der Straeten Breakdown of academic impact, for papers by Unnur Steina Björnsdóttir Breakdown of academic impact, for papers by Nicki M. Nair Breakdown of academic impact, for papers by L. C. Laursen Breakdown of academic impact, for papers by Chiharu Okada Breakdown of academic impact, for papers by Ronald J. Dandurand
Rankless by CCL
2026